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Mycobacterium tuberculosis (TB) has long been one of the leading killers 
worldwide. Approximately one third of the world's population is infected with 
tuberculosis with new cases being reported everyday. It is estimated that in 1999 alone 
there were 3 million deaths as a result of TB. Organisms from Mycobacterium 
tuberculosis are rod-shaped, acid-fast bacilli. On the surface of these bacterium are 
unique lipids termed mycolic acids. Pulmonary M.tuberculosis infections start within the 
alveolar regions. During an infection these bacterium are able to enter inactive, 
pulmonary macrophages by way of receptors. Inside these macrophages the bacteria are 
able to grow and disseminate into other lung tissue. The two factors that decide the 
outcome of a TB infection are the virulence of the pathogen and the host's immune 
response. Less virulent strains of tuberculosis attacking a well-functioning immune 
system may not result in infection. However, in individuals with weaker immune 
systems or in cases of highly virulent strains the disease can progress into highly 
contagious, active tuberculosis. Virulence factors playa major role in TB infections. 
Such factors as TACO, LAM and hemolysin contribute to mycobacterium's ability to 
infect and reproduce within the host. Symptoms of a TB infection are mainly a result of 
the host immune response. The bacteria doesn't cause damage to the host tissue, rather 
the damage is done in the form of necrosis stimulated by the delayed-type 




Tuberculosis (TB) has killed more people than any other infectious agent. It has 
often been called the "White Death" because of the number of Jives it has taken over the 
years. Developing countries are where the highest percentages of deaths occur as a result 
of TB. The lack of capital, to pay for treatments and for health workers to monitor this 
disease, is a large obstacle that many third-world countries are faced with in the fight 
against TB. Because of the complexity and durability of this organism it is difficult to 
understand and treat. By understanding the mechanisms and behaviors behind a TB 
infection new treatments can be developed that are more effective and require a smaller 
duration of treatment. 
The recent rise of mUltiple drug-resistant strains poses a new and more complex 
problem. The world is currently in a race to find effective methods to control the spread 
of this ubiquitous pathogen, a race that TB has long been winning. New techniques and 
initiatives need to be developed to eradicate this disease and eliminate the threat that the 
world's most deadly infectious agent poses. Through research for new vaccines and 
treatments against TB, the world can hope to someday overcome this obstacle and focus 
its research energy on treating and controlling other infectious agents. 
III. Methods 
Research for this paper was gathered using the internet-based Pubmed database as 
well as the UT version, Medline. Searches were focused upon virulence factors, entry of 
TB, drugs, world impact of TB, and the host immune response. The following sections 
reflect the focus of these searches. Texts were also used to provide both general and 
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specific information on pulmonary TB infections. Most of the information used was 
available from multiple review articles. Crosschecking of this information provided 
assurance that the information was based upon commonly held beliefs instead of isolated 
supposition. The comparisons made between articles and text should provide information 
that is relatively accurate. 
The initial search came up with specific articles that addressed a very narrow area 
but were spread over a wide range of topics. The searches were slowly refined until 
papers, which gave broad overviews of TB infection, were found. These papers were 
used to decide topics to address. The information used was based upon agreement 
between more than one source. Any ideas that weren't supported by a general consensus 
or opinions that were irrelevant were not used. 
IV. Body 
A. Overview of Tuberculosis infection 
M.tuberculosis enters the body through inhalation of the pathogen and the 
subsequent infection of pulmonary macrophages. Once inside the lung, macrophage 
receptors recognize the mycobacterium and take up the pathogen into an immature 
phagosome. Typical pathogens that enter macrophages would be normally degraded in 
lysosomes. Within M.tuberculosis, in the context of active infection, this does not occur. 
The mycobacteria are able to resist lysosomal degradation and even multiply within the 
macrophage phagosome. There are two factors that influence the outcome of an infection 
with M.tuberculosis: the virulence of the pathogen and the host response to the infection. 
Because these two factors have different effects in different circumstances, the range and 
outcome of tuberculosis infection varies greatly. Less virulent strains of tuberculosis 
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attacking a well-functioning immune system may not result in infection. In a case like 
this, the bacteria are either killed or go into a dormant state in which disease progression 
does not occur. In individuals with weaker immune systems or in cases of highly virulent 
strains the disease can progress into highly contagious, active tuberculosis. 
In the first case, a host macrophage phagocytoses the pathogen and is able to 
either kill the pathogen or contain it within granulomas. Granulomas are lymphocyte-
surrounded lesions that contain macrophages and M.tuberculosis bacilli. These 
granulomas control growth by creating an anoxic environment in which the pathogen 
cannot reproduce. This environment stimulates the pathogen to shut down its major 
metabolic pathways and enter into a state of dormancy called nonreplication persistence 
(NRP) (1). The bacilli stay dormant for several years and can only be reactivated if the 
host's immune system is compromised. In infected individuals with this type of passive 
infection there are no symptoms of disease and the infection is not contagious. 
Active TB infections have completely different symptoms than passive TB 
infections. In active TB the bacilli can still enter macrophages but the macrophage is 
unable to control the growth of the pathogen. The ability of the macrophage appears to 
be dependent upon the state of activation of effector cells such as CD4+ helper T -cells 
(2). Eventually lysis of the macrophage occurs and the pathogen is released to the extra-
cellular environment and is able to infect other cells. The ability to control the 
proliferation of M.tuberculosis within the macrophage is the critical difference between 
active and passive TB infection. 
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B. Characteristics of Mycobacterium 
Organisms from the genus Mycobacterium consist of rod-shaped, acid-fast baciHi. 
On the surface of mycobacterium are unique 
lipids termed mycolic acids. Mycolic acids 
have played a significant role in the 
identification of members of this genus (3,4). 
Mycolic acids are attached to peptidoglycan on 




1 I I 
OH R2 
Fig. 1. Structure of Mycolic acid; Rl and 
R2 are long-chain aliphatic hydrocarbons 
Taken from: Madigan et.a!., 2000 
with low-permeability. This waxy surface is important for survival of Mycobacteria, but 
it is also a cause for the slow growth of Mycobacterium tubercuLosis (Mtb). The low 
permeability of mycobacteria prevent the organism from being easily classified by the 
Gram stain. To classify Mycobacterium according to the Gram method it is necessary to 
remove the waxy surface with either alkaline ethanol (3) or by melting the wax barrier 
surrounding the cell wall (5). Once this is done, the remaining cell stains Gram positive. 
On solid media M.tubercuLosis shows growth that results in tight, wrinkled 
colonies that clump in their growth patterns. It is thought that the hydrophobic nature of 
the bacilli's cell wall contributes to this unusual pattern (3). M.tubercuLosis requires days 
to weeks of incubation before a culture will have large enough colonies to work with. 
Egg-yolk is typically used in the culturing of mycobacteria because it is a source of lipids 
that the bacilli can make use of within its cell wall (3). M.tubercuLosis was first 
extensively studied by Robert Koch and was one of the first studies to apply the four 
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criteria of Koch's postulates. One of the more unique properties of mycobacteria is their 
generation of yellow carotenoid pigments. M.tuberculosis create these pigments when 
the organism is cultured in light. Carotenoid pigment formation requires short-
wavelength light and O2 (3). The probable use of carotenoid is in the protection of the 
mycobacteria from oxidative damage by singlet O2 formation (3). Virulence within 
M.tuberculosis has been associated with cord factor. This glycolipid causes the 
formation of long, cordlike structures when grown on agar medium (3). The cord shape 
is a result of the intertwining of long chains of bacilli. 
c. Host Immune Response 
The body's response to M.tuberculosis is critical to the infection process. 
Damage done to host tissue is typically self-induced. Much of this damage is from such 
events as the formation of granulomas, sustained macrophage activation and fibrosis of 
lung tissue. All of these events are methods that the immune system uses to contain the 
bacteria but these eventually lead to significant host damage. The host response to an 
M.tuberculosis infection occurs in a cycle that, in active tuberculosis, is perpetuated until 
either the disease is eliminated or the death of the host occurs. 
1. Host-cell entry 
Receptor-ligand interactions play an important role in the entry of pathogen into 
the host macrophage. The type of receptor used in uptake is also thought to be crucial in 
whether a diseased state occurs. Two types of entry are possible into the macrophage: an 
uptake that results in productive infection vs. an uptake that leads to an abortive invasion 
(6). With these two types of receptor-mediated uptake, macrophages can serve as either a 
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refuge for the pathogen or as its killer. Which route the infection takes within the 
macrophage is thought to be dependent upon which receptors are involved in the uptake 
of M.tuberculosis. 
Although still up for debate, several have considered Fc receptors to be 
responsible for abortive invasion by M.tuberculosis (6). In this suggested mechanism 
FcyRI! receptors recognize antibody-opsonized pathogen. After recognition and uptake 
of the mycobacterium by way of these receptors the macrophage attacks the pathogen 
with reactive oxygen and nitrogen intermediates (6). This attack has lead to continued 
research into whether receptor type is a determining factor in pathogen survival. In some 
studies it was found that the viability of bacteria taken up by Fc receptors is significantly 
decreased, while other studies have shown that the viability after uptake is the same. 
Complement and mannose receptors are largely responsible for entry within productive 
infections. Mycobacteria contain both LAM and a phenolic glycolipid that are able to 
bind to the thioester bond on complement factor C3 (6). This binding of C3 to the 
surface of M.tuberculosis provides for rapid uptake of the pathogen into the macrophage 
by way of complement receptors 1,2 and 3 (7). These receptors do not trigger strong 
microbicidal behavior which allow for entry of the pathogen but do not cause its 
destruction (6). 
2. Intracellular control of infection 
The ability of M.tuberculosis to establish an intracellular infection is dependent 
upon the acidification level of its phagosome and the fusion of lysosomes. The activation 
level of the macrophage serves as the most important determinant in whether an infection 
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is controlled. Higher levels of 
activation within the macrophage 
create endosomal environments less 
favorable for M.tuberculosis growth. 
If the endosome maturation is halted 
at an early stage then the 
mycobacteria will not be attacked by 
enzymes, acid, intensive ROI and 
RNI attacks, and the mycobacteria 
will still have access to nutrients, 
of which iron is the most essential. 
M.tuberculosis is able to halt the 
phagosome maturation through 
Fig. 2. Representation of a granuloma. Note the red 
mycobacterium in the center surrounded by single and 
multi-nucleated macrophages. Lymphocytes surround 
the granuloma and playa role in effector functions. 
Granulomas are dry, low oxygen environments. 
Taken from Raupach and Kaufmann, 2001 
such virulence factors as TACO, which is thought to prevent lysosome fusion by 
preventing microtubule formation on the phagosome. 
Two types of responses can take place within sites of M.tuberculosis infection. 
Cell-mediated immunity (CMI) is beneficial in eliminating the infection without 
damaging host tissue. This response expands the number of T -cells within the infection 
site that are able to produce cytokines. The important cytokines produced by T -cells 
include interferon-y (IFN-y) and tumor necrosis factor-a (TNF-a) (6,8). IFN-y is able to 
bind to macrophage and cause autocrine stimulation by way of interleukin-12 (IL-12) (8). 
An effective CMI response is the ideal way to have a TB infection controlled. The bacilli 
are ingested and killed by macrophages without extensive necrosis of pulmonary tissue. 
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The other possible immune response, delayed-type hypersensitivity (DTH), is 
destructive to host tissue and is responsible for the symptoms of tuberculosis. Although 
controlled by the same Thl-type T-cells as CMI, DTH responses result in extensive tissue 
necrosis and scar tissue formation (8). The difference is seen when the levels of bacterial 
antigens reach high levels within the infection site. This high level of stimulation by 
these antigens causes the death of unstimulated, bacilli-laden macrophages and the 
surrounding tissue. Much of this damage can be attributed to stimulation by CD8 
cytotoxic T-cells (9,10). The initial immune response is typically a delayed-type 
hypersensitivity because the majority of macrophages are in an inactive state (8). The 
caseation of the tissue controls growth until activated macrophages are able to intervene 
and stop infection. 
The area in which an infection and immune response occurs is commonly known 
as a tubercle or in cases of advanced infection, a granuloma. This area consists of 
inactive macrophages in the center, surrounded by activated macrophages and 
lymphocytes (2,11). On the outside of these activated cells is another group of na'ive, 
inactive macrophages that have been attracted by way of chemotaxis to the site of 
infection (2) . Sometimes mycobacteria can escape the tubercle and infect these outer 
macrophages. When this occurs a new tubercle is developed and the CMI must be 
reactivated. This spread of the bacterium out of the tubercles is responsible for the 
pulmonary spread of tuberculosis (8). For the body to control infection it must be able to 
contain the infection and not allow dissemination of the bacilli. When the immune 
system is unable to kill the pathogen within the center of the tubercle then fusion of the 
inactivated, bacilli-laden macrophages occur resulting in the formation of a granuloma 
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(12). Tissue death around this granuloma occurs creates an anoxic, dry environment (12). 
This unfavorable environment signals the bacilli to go into a dormant non-reproductive 
state in which further spread of bacilli is prevented. Unless stimulated by heat and 
oxygen, the bacilli can stay in this low metabolic state indefinitely (1,13). 
3. Effector mechanisms 
Developed resistance to TB infection depends upon Thl-cell mobilization. Thl 
cells are extremely important within CMI immune responses. These cells produce IFN-y, 
IL-2 and lymphotoxin, which are essential in activating the microbicidal activity of 
macrophages (2,11). 
Mycobacterium-laden macrophages 
release TNF-a, and IL-12, which 
stimulate Thl helper cells and 
natural killer (NK) cells and attract 
new lymphocytes to the site of 
TNF-U 
+ IL-12 
infection by way of chemotaxis 
(6,11). TNF-a serves both autocrine 
Fig. 3. Overview of lymphocyte-macrophage interaction. 
Note that IL-12 and TNF-alpha upregulate secretion of 
Interferon. IL-lO downregulates NK and Th 1 secretion of 
lFN-gamma. 
Taken from: Schluger et.a!. 1998 
and paracrine activating functions 
while IL-12 is solely paracrine (2). After stimulation by IL-12, NK and Thl cells 
releases JFN- y, which significantly increases the activation level ofthe macrophage (11). 
After the initial infection, macrophages also secrete IL-l, IL-3, IL-6 and macrophage 
chemoattractant protein 1 (MCP-1) (6). These cytokines chemotactically recruit 
lymphocytes and nai'Ve macrophages to the site of infection. After an infection is 
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controlled, the macrophage release IL-lO which self-inactivates the macrophage as well 
as surrounding lymophocytes and NK cells (2). 
The methods in which the various lymphocytes and monocytes work together to 
control infection is a complex process. Some of these cells have been found to be 
important in controlling M.tuberculosis but the contribution they make to the immune 
response is still unclear. "f/8 T -lymphocytes and CD8 cytotoxic T -cells have been found 
to play an important role in the control of tuberculosis infections (8,11). "f18 T-
lymphocytes are known to recognize non-protein antigens that do not have to be 
displayed by the major histocompatibility complex (MHC) (8). One of the more 
important antigens that these lymphocytes recognize is cord factor (trehalose dimycolate) 
(8). These lymphocytes also appear to be important in resistance to clinical tuberculosis 
among tuberculin-positive health care workers (8). 
The role that CD8 T-cells play in a tuberculosis infection is also important but not 
as critical as that of Th 1 cells. Within the murine model, CD8-KO mice were unable to 
control the infection resulting in eventual death of the mice (9). Turner et.a!' have shown 
that CD8 T-cells use the CD95/CD95L (Fas-FasL) pathway to trigger the infected 
macrophage to go in to apoptosis (9). It is believed that the apoptotic death mediated by 
CD8 T-cells serves to release viable bacteria from inactive macrophages and allow for 
the pathogens uptake into active macrophages (8,9,10). This release and subsequent 
uptake prevents uncontrolled proliferation of the bacilli within macrophages (10). 
Extensive DTH activation of CD8 T-cells causes much of the damage to host tissue. The 
extended presence of lymphocytes, neutrophils and macrophages cause damage to host 
tissue through the cytokines produced. Another lymphocyte thought to be important 
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within a TB infection is CD I-restricted T -cells. The exact role these cells serve is 
unclear, however they are thought to be involved in recognizing glycolipids that are 
expressed on M.tuberculosis while it is in a phagosome (14). 
D. Virulence factors of M.tuberculosis 
Unlike the majority of pathogenic bacteria, tuberculosis does not contain a toxin 
that causes damage within host tissue. Instead the destruction comes from the host 
immune response. Although there is no toxin, M.tuberculosis does contain several 
virulence factors that help the bacterium survive. The majority of these virulence factors 
are involved with entry of the pathogen into host macrophages and the proliferation of the 
mycobacteria once inside this host tissue. One studied virulence factor is the recruitment 
of a 50kDa phagosome coat protein TACO (tryptophan aspartate-containing coat protein) 
(15). This protein was characterized and analyzed extensively in 1999 and is found on 
the membranes of phagosomes containing pathogen (15). Endosomes that don't contain 
this protein are able to mature into or bind to mycobacterium-killing lysosomes (15,16). 
These lysosomes kill the bacteria through enzymatic and acidic degradation and are 
essential in host immune defenses. When TACO is present within the phagosome 
membrane, the membrane is unable to mature and bind to cellular lysosomes (15,16). 
TACO is a member of the family of WD repeat proteins and is produced within 
host tissue (15). The WD proteins are have not been found within prokaryotes and are 
typically involved in signal transduction, motility, cytoskelatal organization and vesicle 
fusion (15). It is thought that TACO plays a role in tubulin recruitment within the host 
cell. This interaction implies that TACO is involved in microtubule formation (15). 
13 
Greg Dunn 
Within cells not infected 
with M.tuberculosis, TACO is 
probably a signal to prevent 
lysosomal binding (15). The 
mechanism by which TACO is 
recruited by M.tuberculosis is 
unknown, however it is thought 
that the interaction with 
M.tuberuculosis-containing 
---~,-
, Late endosome 
Fig. 4. Diagram showing the effect of TACO upon Mycobacterium 
tuberculosis virulence. When TACO is not recruited then Iysosomes can 
fuse and destroy the pathogen. 
Taken from: Ferrari et.a!. 1999 
phagosomes occurs through association with cholesterol (16). One interesting fact is that 
TACO is not present within Kupffer cells in the liver. It appears that these liver cells 
naturally down-regulate TACO, which may partially explain why the liver is the site of 
mycobacterium removal in the body (15). 
Another virulence factor important in M.tuberculosis infections is involved in 
entry of mycobacteria into the host macrophage. Phagocytic uptake into macrophages 
requires the binding of pathogen to macrophage receptors. These receptors include 
complement receptors, mannose receptors, scavenger receptors and Fc receptors that 
take-up antibody bound bacteria (17). It appears that mycobacteria contain a receptor 
that is capable of binding cholesterol found within macrophage cell membranes. When 
cholesterol is removed from macrophages, it has been found that M.tuberculosis is unable 
to enter into host macrophages (16). Once these initial interactions take place then other 
macrophage receptors interact and take-up the bacterium (16). 
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There appears to be another factor at work that remains undefined but active 
within mycobacterial phagosomes. This factor blocks the transport and maturation steps 
between early and late endosomes. Within these phagosomes expression of rab7 is not 
seen. Rab7 is a GTPase that is found in late endosomes and is suspected of regulating 
traffic within the membranes of mature endosomes (16). Rab5 expression is typically 
found to indicate lack of rab7 and is typically associated with early endosomes (16). This 
protein is indeed found within phagosomes that contain live, propagating mycobacteria 
(16). Whether TACO or some other factor is responsible for the blocking of rab7 
expression is to be determined, however it is apparent that the factor responsible for this 
activity is essential in M.tuberculosis virulence. Limited acidification of the endosome is 
also seen within phagosomes (16). This low acidification is due to an unknown or 
undefined M. tuberculosis virulence factor that prevents the production of the proton-
ATPase responsible for the acidification of the phagosome. 
The myobacterial cell envelope largely consists of a mycolyl arabinogalactan-
peptidoglycan complex and associated lipoarabinomannan (LAM), a glycolipid. It is 
thought that the lipids within the cell envelope mediate specific interactions with host 
ligands or membranes and serve as lesser virulence factors (4). It is suggested that one of 
the reasons for LAMs importance in the cell is that it prevents macrophage and leukocyte 
activation (18). How this is done is unknown, but tests comparing lipoarabinomannan 
types indicate variations in the levels of activation. M.tuberculosis LAM appears to elicit 
a chemotactic response but whether this is important or not is unknown. It is thought that 
the response of T -cells to the site of infection might allow the pathogen to signal the T-
cells into a state of anergy (deactivation) (18). Unfortunately this is just speculation since 
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the real mechanism and purpose is unknown. Another interesting trait of bacteria 
containing LAM is that the chemotactic, granulocytic response was not present (18). A 
lack of neutrophils was found within the strains of M.tuberculosis that contained the 
virulent form of LAM (18). A final trait of LAM is that it might prevent the production 
of reactive oxygen intermediates (11). This ability combined with the reduced 
acidification present within the phagosome would help prevent M.tuberculosis 
destruction . 
A final virulence factor is hemolysin (11,19). This factor is thought to be 
responsible for lysing the phagosome containing the pathogen. This releases the 
M.tuberculosis into the cytoplasm of the macrophage where lysosomes and other factors 
cannot contribute to the destruction of the pathogen (11,20,21). Without the presence of 
lysosomal fusion, acidification, or superoxide attack M.tuberculosis is able to freely 
divide and is eventually released from the host macrophage. It is unclear how important 
this factor is to overall infection but if M.tuberculosis is able to move into the cytoplasm, 
uncontrolled population expansion can easily take place. 
E. Current treatments and vaccines against tuberculosis 
Vaccines and antibiotics that are effective against TB have been very difficult to 
find. The difficulty in finding vaccines is that antigens that stimulate an effective 
antibody response haven't been found . Drugs are difficult to fine because mycobacteria 
have both inherent and conferred resistance to almost every single antibiotic. The 
inherent resistance is due to both the mycolic acid surface as well as the difficulty of 
diffusion through a fibrous granuloma or tubercle. There are four populations that bacilli 
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might fall under: active and extracellular within cavities, in closed tubercles, within 
macrophages and dormant. Because no antibiotic is effective against all four of these 
populations, treatment that makes use of a cocktail of antibiotics is necessary. These 
factors combine to make the eradication of Mtb a daunting task. 
1. Vaccines 
BCG (bacillus Calmette-Guerin) is currently the only vaccine available against 
tuberculosis. Calmette and Guerin in 1906 originally observed TB resistance when pigs 
where inoculated with an equine strain of Mycobacteria. After modification of a bovine 
strain they were finally able to come up with the BCG vaccine that was recommended, in 
1928, by the League of Nations for widespread use (21). The BCG vaccine varies in 
immune protection from 0% to 80% depending upon which strain is involved (20). This 
level of efficacy is too low to have much of an effect in controlling the spread. BCG only 
delayed the spread of TB for a few years by selecting against the strains that BCG was 
effective against. The countries that have the greatest burden from tuberculosis are the 
ones in which the BCG vaccine is least effective (20). 
More effective vaccines need to be developed against TB. One type of vaccine 
that has been considered uses a recombinant BCG strain (14,20,21). This strain has a 
gene for hemolysin, the protein that allows M.tuberculosis to escape into the cytoplasm 
(20,21). Another recombinant BCG strain that expressed Ag85A1B/C in high amounts 
increased the efficacy of the vaccine (20). Other antigens to place within recombinant 
strains are being looked at but very few have been found that increase resistance to TB. 
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Two other approaches to vaccines include protein subunit vaccines and DNA 
vaccines (19,20,21,). Subunit vaccines use proteins that stimulate an immune response. 
Two of the subunit vaccine types being considered are secreted proteins and stress 
proteins that are synthesized by the bacteria during the later stages of infection (19). The 
subunit approach requires that antigens which produce an immune response are located 
and presented to the immune system in a way that stimulates a response (14). The 
subunit approach is preferred in many ways because the chance of vaccine-related illness 
occurring is greatly reduced. DNA vaccines are also being considered. By inserting 
DNA that expresses mycobacterial antigens into a retrovirus, the production of the 
antigens allow for an immune response to be initiated (19). This approach is favorable to 
the subunit method because there aren't purification and packaging problems that are 
inherent with subunit vaccines (19). Both hemolysin and Ag85 are antigens that can be 
used within subunit and DNA vaccines. If a subunit or DNA vaccine is eventually 
developed then it is likely that several antigens or their genes will be expressed or present 
within the vaccine. 
2. Chemotherapy 
Isonazid, rifampin and pyrazinamide have been the front-line, anti-tuberculosis 
drugs since the 1950s (22). All three of these drugs have Minimal Inhibitory 
Concentrations (MlCs) that are close to the concentration in which they become toxic to 
host tissue (22). This shows the ineffectiveness of these drugs and emphasizes the need 
for more effective treatments. These three drugs are the only bactericidal, front-line 
treatments (23). These three drugs are all prodrugs that become effective when they are 
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modified by M. tuberculosis enzymes (22). Unfortunately the rise of drug resistant TB 
strains occurs quickly in the presence of prodrugs. This attribute is seen because one 
mutation in the gene responsible for converting the drugs into their active form is all that 
is needed to confer resistance. Two other drugs, ethambutol and streptomycin, are 
considered front-line drugs (23). These are bacteriostatic and are effective in 
complementing the immune system or the other first-line drugs. 
Very little is known of the targets and activity of many of the front-line anti-TB 
drugs. Studies of isonazid found that after treatment with INH the specimens lost their 
acid-fastness (24). This implies that isonazid interferes with mycolic acid synthesis 
thereby hindering the biosynthesis of the bacterial cell wall (24,25). Point mutations 
within the inhA gene confer mycobacterial resistance to isonazid (24). Rifampin is 
known for its rapid diffusion across the mycobacterial cell envelope and its activity 
against RNA polymerase (24). Mutations in the gene coding for the ~-subunit of RNA 
polymerase frequently confers resistance to rifampin (24). The mode of action for the 
third, front-line anti-TB drug, pyrazinamide, is unknown. Resistance to this gene is 
conferred when mutations in the pncA gene are present. This drug is active against 
bacilli in low pH environments (such as a phagosome) after it is converted to pyrazinoic 
acid (24). The two, less important first-line drugs, ethambutol and streptomycin, have 
bacteriostatic modes of action. Ethambutol is thought to interfere with glucose 
incorporation into cell wall polymers, while streptomycin is thought to interfere with the 




The current repertoire of TB drugs is very limited and with the rise in MDR 
strains of TB, new drugs need to be developed. There are several different approaches to 
finding new drugs. Modification of the current front-line and second-line TB drugs 
shows promise, although in many cases the bacterial resistance against these drugs is 
preserved (24). The search for new antibiotics might also yield a new drug that is 
effective against TB. A third method of finding new anti-TB drugs might make use of 
computer protein modeling to determine drug-pathogen interactions (24). It has been 
found that, in general, the more hydrophobic an antibiotic is, the greater its potency (22). 
Another factor that would help in the development of new antibiotics is finding drugs that 
do not require modification by the mycobacterium before they become effective. This 
attribute would prevent the bacterium from developing immunity as quickly and as 
effectively (22). 
F. World strategies and initiatives against Tuberculosis 
Mycobacterium tuberculosis (TB) has long been one of the leading killers 
worldwide. Approximately one third of the world's population is infected, with new 
cases being reported everyday. It is estimated that in 1999 alone there were 8.4 million 
new cases (26). This was an increase from the estimated 8.0 million new cases estimated 
in 1997 (26) . Tuberculosis isn't just a problem within developing countries. The United 
States has seen a sharp increase of cases due to lagging public policy as well as the 
increase in cases of MDR (Multi-drug resistant) TB strains (27). These MDR resistant 
strains can only be treated with less effective antibiotics that the bacilli haven't developed 
resistance to. More effective antibiotics are needed to treat these new strains. 
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In 1992 the WHO (World Health Organization) declared TB a global emergency, 
an unprecedented step. Initiatives have since been adopted by the WHO that call for the 
reduction and eventual elimination of TB. These initiatives call for detection of 70% of 
new cases of TB and the effective treatment of 85% of these cases by the year 2005 (26). 
Unfortunately the WHO is a long way away from these objectives. Instead of reaching 
these objectives by 2005 it is estimated that these goals won't be reached until 2013 (26). 
DOTS (Directly Observed Treatment, Short-course) is the strategy recommended by the 
WHO to help reach these goals TB. DOTS consists of five key components (26): 
• Government commitment to sustained TB control activities. 
• Case detection by sputum smear microscopy among symptomatic patients self-
reporting to health services. 
• Standardized treatment regimen of six to eight months for at least all sputum 
smear positive cases, with directly observed therapy (DOT) for at least the initial 
two months. 
• A regular, uninterrupted supply of all essential anti-TB drugs. 
• A standardized recording and reporting system that allows assessment of 
treatment results for each patient and of the TB control program performance 
overall. 
TakenJrom: The World Healrh Report, 2001 
The DOTS method of treatment calls for individually tailored treatment of TB. This is 
necessary because of the ineffectiveness of antibiotics on MDR strains. In extreme cases 
in which the drugs available for treatment are ineffective, the infected section of the lung 
has to be surgically removed. The complexity inherent in treating patients with MDR 
requires significant human resources. This cost is necessary because failure to reduce 
worldwide TB infection could see the rise in new MDR strains that are easily spread and 
cannot be treated. The WHO compares this possibility as having a threat akin to the HIY 




Pulmonary tuberculosis infections rely on a unique balance between the host 
immune response and the virulence factors present within the pathogen. Survival in a 
pulmonary macrophage requires that such virulence factors as TACO recruitment and 
LAM be expressed by the bacterium. M.tuberculosis prevents its destruction within host 
macrophages by preventing lysosome-phagosome fusion and by preventing acidification 
of the endosome. The waxy mycolic acids surrounding the pathogen also serve many 
functions that prevent the destruction of the pathogen within macrophages. Control of 
TB infections require that macrophages be activated by Thl helper T-cells and by natural 
killer cells. This activation is controlled by the release and uptake of cytokines essential 
in activation of the CMI and DTH immune responses. 
Tuberculosis has long been a complex and devastating world problem. The lack 
of initiative, consistency and discipline in monitoring and treating tuberculosis has lead to 
a state of near uncontrolled spread of TB. World initiatives need to be adhered to by each 
country to help control the spread of this disease. New vaccines, effective in developing 
a host immune response against sustained TB infections, would greatly reduce the impact 
this disease has upon the world. New drugs also need to be developed that provide 
effective treatment against the MDR strains that have arisen. Increases in public sector 
spending on TB research are the best way to develop these new therapies. Because TB is 
largely a third world disease, any new therapies developed would not have a great capital 
demand. This lack of capital necessitates public-sector development since 
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